Dublin, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The "Neuroendocrine Tumors - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering.
The "Neuroendocrine Tumors - Pipeline Insight, 2025" report delivers an in-depth analysis of the current landscape and future prospects for neuroendocrine tumors (NETs). Encompassing data on over 70 companies and 75 pipeline drugs, this report details clinical and nonclinical stage drugs, with particular focus on therapeutics evaluation by product type, stage, administration route, and molecule type. It also sheds light on inactive pipeline products within this domain.
NETs originate from neuroendocrine system cells, possessing both endocrine cell and nerve cell traits, and can produce specific hormones. Functional NETs secrete excess hormones affecting body organs, while nonfunctional NETs do not produce enough to cause symptoms. The symptomatology and treatment plans vary based on this functionality. Notably, about 60% of NETs are nonfunctional, requiring different therapeutic strategies compared to their functional counterparts.
Early detection of NETs remains challenging due to the lack of universal symptoms, often being discovered incidentally during unrelated treatments. Comprehensive diagnosis involves the coordination of medical oncologists, surgeons, and pathologists, integrating pathology reports, hormonal testing, and imaging for a complete diagnostic overview. Surgical removal remains a primary treatment, especially for localized tumors.
The report highlights the latest guidelines for NET treatment, including a commercial and clinical assessment of emerging drugs. Detailed descriptions cover the drugs' mechanisms of action, clinical trial results, regulatory approvals, and other developmental details. This section also explores industry dynamics, such as collaborations, mergers, and funding activities, providing a holistic view of the NET therapeutic landscape.
Report Highlights:
- Current R&D efforts targeting NETs are exploring innovative therapies.
- A detailed view of drugs at various development stages is provided, from Phase III to discovery phase, along with information on trial collaborations, pharmacological actions, and more.
- Featured emerging drugs include CAM2029 by Camurus, targeting rare diseases with a focus on improved octreotide delivery and patient convenience; AlphaMedix by Orano Med, designed for somatostatin receptor targeting; and Voyager-V1 by Vyriad, Inc., engineered for selective cancer cell replication and destruction.
Key Insights:
- Neuroendocrine Tumors pipeline analysis with emphasis on unmet needs and potential drug impacts.
- Assessment of commercial opportunities and therapeutic strategies.
- Evaluation of pipeline products, including inactive and discontinued candidates.
Key Topics Covered:
Introduction
Executive Summary
Neuroendocrine Tumors: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Neuroendocrine Tumors - Analytical Perspective
Late Stage Products (Phase III)
- Comparative Analysis
CAM2029: Camurus
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
AlphaMedix: Orano Med
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I/II)
- Comparative Analysis
Voyager-V1: Vyriad, Inc.
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Inactive Products
- Comparative Analysis
Neuroendocrine Tumors Key Companies
Neuroendocrine Tumors Key Products
Neuroendocrine Tumors - Unmet Needs
Neuroendocrine Tumors - Market Drivers and Barriers
Neuroendocrine Tumors - Future Perspectives and Conclusion
Neuroendocrine Tumors Analyst Views
Appendix
Companies Featured
- Camurus
- Vyriad, Inc.
- TYK Medicines
- Orano Med
- Advanced Accelerator Applications
- Sinotau Pharmaceutical Group
- ITM Solucin GmbH
- Molecular Targeting Technologies, Inc.
- Biotheus Inc.
- Aadi Bioscience, Inc.
- TaiRx, Inc.
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/gax39j
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
